This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
intensive care | 1103 |
critically ill | 1063 |
ill patients | 792 |
acute respiratory | 690 |
critical care | 670 |
mechanical ventilation | 667 |
septic shock | 608 |
care unit | 599 |
respiratory distress | 456 |
distress syndrome | 423 |
respiratory failure | 416 |
hospital mortality | 349 |
icu admission | 349 |
risk factors | 343 |
lung injury | 335 |
cardiac arrest | 315 |
icu patients | 287 |
patients admitted | 287 |
organ failure | 249 |
critical illness | 238 |
severe sepsis | 223 |
mechanically ventilated | 211 |
day mortality | 209 |
icu stay | 203 |
mortality rate | 202 |
two groups | 201 |
observational study | 199 |
cohort study | 191 |
sofa score | 189 |
acquired pneumonia | 188 |
systematic review | 187 |
significantly higher | 185 |
crit care | 184 |
severe acute | 182 |
respiratory syndrome | 181 |
doc id | 177 |
cord uid | 177 |
care doi | 177 |
organ dysfunction | 175 |
adult patients | 170 |
acute lung | 168 |
apache ii | 162 |
respiratory tract | 160 |
ards patients | 157 |
membrane oxygenation | 154 |
hospitalized patients | 153 |
ml kg | 151 |
extracorporeal membrane | 150 |
kidney injury | 147 |
ventilated patients | 146 |
control group | 145 |
coronavirus disease | 144 |
acute kidney | 143 |
care units | 139 |
among patients | 138 |
emergency department | 138 |
signifi cant | 137 |
randomized controlled | 137 |
associated pneumonia | 136 |
statistically significant | 136 |
risk factor | 134 |
additional file | 133 |
signifi cantly | 130 |
brain injury | 129 |
fi rst | 127 |
renal replacement | 126 |
springer nature | 125 |
institutional affiliations | 125 |
inflammatory response | 125 |
nature remains | 125 |
published maps | 125 |
jurisdictional claims | 125 |
patients undergoing | 125 |
remains neutral | 125 |
tidal volume | 125 |
cardiac surgery | 124 |
logistic regression | 123 |
significant difference | 122 |
replacement therapy | 121 |
novel coronavirus | 119 |
septic patients | 118 |
clinical practice | 117 |
high risk | 117 |
patients without | 115 |
mean age | 115 |
controlled trial | 112 |
influenza virus | 111 |
patients receiving | 111 |
severe disease | 110 |
care medicine | 108 |
mortality rates | 108 |
blood pressure | 108 |
note springer | 107 |
competing interests | 107 |
present study | 105 |
patients received | 105 |
pao fio | 105 |
university hospital | 105 |
retrospective study | 105 |
informed consent | 104 |
study period | 103 |
clinical outcomes | 102 |
clinical characteristics | 102 |
clinical trial | 101 |
fluid balance | 101 |
primary outcome | 99 |
mg kg | 99 |
icu mortality | 99 |
ii score | 98 |
patients treated | 97 |
significantly lower | 97 |
within hours | 96 |
blood flow | 95 |
virus infection | 94 |
cuff leak | 94 |
fl uid | 93 |
multiple organ | 92 |
performed using | 92 |
hospital stay | 92 |
hospital discharge | 91 |
spontaneous breathing | 91 |
mg dl | 90 |
authors declare | 90 |
invasive mechanical | 90 |
health care | 90 |
confidence interval | 89 |
respiratory support | 89 |
pandemic influenza | 89 |
final manuscript | 88 |
failure assessment | 88 |
prone positioning | 88 |
avian influenza | 88 |
immune response | 87 |
heart failure | 87 |
least one | 87 |
fluid resuscitation | 86 |
respiratory rate | 86 |
increased mortality | 86 |
lower respiratory | 86 |
factors associated | 85 |
prospective observational | 85 |
significant differences | 84 |
nasal cannula | 84 |
leak test | 84 |
renal failure | 84 |
adverse events | 84 |
previous studies | 83 |
included patients | 83 |
inclusion criteria | 82 |
antibiotic therapy | 81 |
hospital admission | 80 |
viral load | 79 |
diff erence | 79 |
ng ml | 78 |
syndrome coronavirus | 77 |
flow nasal | 77 |
oxygen therapy | 77 |
severe covid | 76 |
statistical analysis | 75 |
ethics approval | 75 |
regression analysis | 75 |
expiratory pressure | 75 |
eff ect | 75 |
invasive ventilation | 74 |
prospective study | 74 |
hospital cardiac | 74 |
clinical trials | 74 |
traumatic brain | 73 |
body weight | 73 |
odds ratio | 73 |
authors read | 72 |
reactive protein | 72 |
arterial pressure | 72 |
retrospective cohort | 71 |
animal models | 71 |
diff erent | 71 |
ethics committee | 71 |
central venous | 71 |
higher mortality | 71 |
sequential organ | 71 |
severe ards | 71 |
mean arterial | 70 |
interquartile range | 70 |
acute physiology | 70 |
patients requiring | 69 |
increased risk | 69 |
heart rate | 69 |
pulmonary disease | 68 |
antimicrobial therapy | 68 |
lung biopsy | 67 |
multivariate analysis | 67 |
positive end | 67 |
shock patients | 67 |
endothelial cells | 67 |
independently associated | 66 |
high mortality | 66 |
life support | 66 |
blood gas | 65 |
chronic obstructive | 65 |
icu length | 65 |
induced lung | 65 |
united states | 65 |
predictive value | 65 |
corticosteroid treatment | 65 |
median age | 65 |
noninvasive ventilation | 65 |
years old | 64 |
secondary outcomes | 64 |
free days | 63 |
exclusion criteria | 63 |
sample size | 63 |
epithelial cells | 63 |
infl ammatory | 63 |
retrospective analysis | 62 |
icu discharge | 62 |
middle east | 62 |
infl ammation | 62 |
tidal volumes | 61 |
one patient | 61 |
may also | 60 |
converting enzyme | 60 |
obstructive pulmonary | 60 |
machine learning | 59 |
ecmo support | 59 |
independent risk | 59 |
infection control | 59 |
severe respiratory | 58 |
consecutive patients | 58 |
platelet count | 58 |
east respiratory | 58 |
infectious diseases | 58 |
standard deviation | 58 |
controlled trials | 58 |
within days | 58 |
baseline characteristics | 58 |
arterial blood | 57 |
blood samples | 57 |
pg ml | 57 |
surgical patients | 57 |
patients infected | 56 |
respiratory syncytial | 56 |
berlin definition | 56 |
dead space | 56 |
viral pneumonia | 56 |
gene expression | 55 |
data analysis | 55 |
disease severity | 55 |
hospital length | 55 |
airway pressure | 55 |
data collection | 55 |
endotracheal tube | 54 |
first hours | 54 |
bronchoalveolar lavage | 54 |
open lung | 54 |
two patients | 54 |
randomized clinical | 54 |
clinical features | 54 |
pilot study | 54 |
eff ects | 54 |
clinical course | 54 |
hmgb mab | 53 |
pseudomonas aeruginosa | 53 |
study group | 53 |
time points | 53 |
case series | 52 |
infected patients | 52 |
partial pressure | 52 |
syncytial virus | 52 |
cardiac output | 52 |
related ards | 52 |
myocardial infarction | 52 |
prospective cohort | 51 |
ali ards | 51 |
airway obstruction | 51 |
receiver operating | 51 |
current study | 51 |
angiotensin ii | 50 |
growth factor | 50 |
blood glucose | 50 |
severe cap | 50 |
significantly different | 49 |
identifi ed | 49 |
survival rate | 49 |
obese patients | 49 |
observational studies | 49 |
patients hospitalized | 49 |
poor outcome | 49 |
endothelial cell | 49 |
host response | 49 |
extubation failure | 48 |
diff erences | 48 |
defi cient | 48 |
oxygen saturation | 48 |
patients may | 48 |
sepsis patients | 48 |
cmv reactivation | 47 |
propensity score | 47 |
atrial fibrillation | 47 |
cytokine storm | 47 |
necrosis factor | 47 |
alveolar macrophages | 47 |
staphylococcus aureus | 47 |
dex group | 47 |
lung disease | 47 |
drug delivery | 47 |
respiratory system | 47 |
cardiac injury | 46 |
coronary artery | 46 |
kg min | 46 |
systemic inflammatory | 46 |
collected data | 46 |
fio ratio | 46 |
pressure support | 46 |
acute renal | 45 |
fl ow | 45 |
multicenter study | 45 |
defi ned | 45 |
care patients | 45 |
public health | 45 |
neurological outcome | 45 |
regression model | 45 |
risk patients | 45 |
month period | 45 |
per patient | 44 |
healthy volunteers | 44 |
viral shedding | 44 |
high peep | 44 |
continuous variables | 44 |
significantly increased | 44 |
tumor necrosis | 44 |
cardiogenic shock | 44 |
chronic health | 44 |
antiviral treatment | 44 |
ml min | 44 |
blood transfusion | 44 |
cardiopulmonary bypass | 43 |
analysis showed | 43 |
patient care | 43 |
electrical impedance | 43 |
hypoxemic respiratory | 43 |
first days | 43 |
ards group | 43 |
nervous system | 43 |
medical records | 43 |
enrolled patients | 42 |
may lead | 42 |
retrospective observational | 42 |
impedance tomography | 42 |
critical patients | 42 |
seasonal influenza | 41 |
severe influenza | 41 |
pulmonary embolism | 41 |
world health | 41 |
saps ii | 41 |
systemic inflammation | 41 |
immune responses | 41 |
cant diff | 41 |
elderly patients | 41 |
ang tie | 40 |
age years | 40 |
rib fixation | 40 |
renal function | 40 |
healthy controls | 40 |
clinical data | 40 |
cardiopulmonary resuscitation | 40 |
fi ndings | 40 |
pulmonary edema | 40 |
icu admissions | 40 |
eff ective | 40 |
hospital death | 40 |
red blood | 39 |
primary endpoint | 39 |
randomized trial | 39 |
significantly associated | 39 |
trauma patients | 39 |
decision making | 39 |
statistical significance | 39 |
mortality among | 39 |
may help | 39 |
medical center | 39 |
demographic data | 39 |
prognostic value | 39 |
chain reaction | 38 |
carbon dioxide | 38 |
extubation airway | 38 |
blood loss | 38 |
polymerase chain | 38 |
included studies | 38 |
cognitive dysfunction | 38 |
urine output | 38 |
inflammatory cytokines | 38 |
adverse effects | 37 |
healthy subjects | 37 |
measured using | 37 |
viral replication | 37 |
unit patients | 37 |
univariate analysis | 37 |
streptococcus pneumoniae | 37 |
overall mortality | 37 |
intervention group | 37 |
ill patient | 37 |
innate immune | 37 |
health evaluation | 37 |
icu beds | 37 |
serum creatinine | 37 |
six patients | 37 |
treatment failure | 37 |
health organization | 37 |
polymicrobial aetiology | 37 |
corresponding author | 37 |
medical patients | 36 |
lung ultrasound | 36 |
antibiotic treatment | 36 |
influenza viruses | 36 |
influenza pandemic | 36 |
whole blood | 36 |
operating characteristic | 36 |
maltophilia hap | 36 |
cient mice | 36 |
inflammatory mediators | 36 |
ill adults | 36 |
severe patients | 36 |
patients included | 36 |
intracranial pressure | 36 |
response syndrome | 36 |
high flow | 35 |
polymicrobial pneumonia | 35 |
surviving sepsis | 35 |
surgical icu | 35 |
viral infection | 35 |
four patients | 35 |
blood cell | 35 |
prone position | 35 |
medical intensive | 35 |
plasma levels | 35 |
identify patients | 35 |
higher risk | 35 |
ischemic stroke | 35 |
patient outcomes | 35 |
term mortality | 35 |
bacterial infection | 35 |
acute myocardial | 34 |
energy expenditure | 34 |
hong kong | 34 |
computed tomography | 34 |
ang ii | 34 |
roc curve | 34 |
body mass | 34 |
determine whether | 34 |
diffuse alveolar | 34 |
lung volume | 34 |
serum levels | 34 |
reasonable request | 34 |
recent studies | 34 |
oxygen delivery | 34 |
commonly used | 33 |
assessed using | 33 |
stenotrophomonas maltophilia | 33 |
study design | 33 |
like receptor | 33 |
clinical studies | 33 |
nebulised heparin | 33 |
lung cancer | 33 |
analyzed using | 33 |
antimicrobial treatment | 33 |
icu los | 33 |
poor prognosis | 33 |
severe cases | 33 |
airway management | 33 |
three patients | 33 |
may improve | 33 |
lung compliance | 33 |
influenza infection | 33 |
physiology score | 33 |
one study | 33 |
requiring mechanical | 33 |
patients aged | 32 |
central nervous | 32 |
emergency medicine | 32 |
cov infection | 32 |
sepsis campaign | 32 |
previously reported | 32 |
significantly reduced | 32 |
study included | 32 |
alveolar damage | 32 |
categorical variables | 32 |
driving pressure | 32 |
several studies | 32 |
thoracic society | 32 |
patients using | 32 |
copd patients | 32 |
tertiary care | 32 |
left ventricular | 32 |
mass index | 32 |
type i | 31 |
cc sha | 31 |
drotrecogin alfa | 31 |
diagnostic accuracy | 31 |
inspired oxygen | 31 |
risk stratification | 31 |
previous study | 31 |
lung tissue | 31 |
fluid overload | 31 |
immune system | 31 |
institutional review | 31 |
organ system | 30 |
blood cells | 30 |
linear regression | 30 |
year period | 30 |
nitric oxide | 30 |
patient safety | 30 |
day survival | 30 |
cox regression | 30 |
mdr pathogens | 30 |
severely ill | 30 |
shear modulus | 30 |
niv group | 30 |
mainland china | 30 |
exact test | 30 |
significant decrease | 30 |
median time | 30 |
patients died | 30 |
healthcare workers | 30 |
case report | 30 |
pulmonary dysfunction | 30 |
may contribute | 30 |
lung function | 30 |
lung microbiome | 30 |
statistically signifi | 30 |
data suggest | 30 |
nosocomial infections | 30 |
fluid administration | 30 |
ecmo patients | 30 |
serum iron | 30 |
ventilatory support | 30 |
patients showed | 30 |
nursing staff | 30 |
support ventilation | 29 |
patient population | 29 |
association studies | 29 |
respiratory infections | 29 |
ventilator settings | 29 |
higher levels | 29 |
may cause | 29 |
gut microbiota | 29 |
calculated using | 29 |
rrt group | 29 |
considered statistically | 29 |
simplified acute | 29 |
therapeutic hypothermia | 29 |
influenza pneumonia | 29 |
surgery patients | 29 |
organ injury | 29 |
icu group | 29 |
disease control | 29 |
practice guidelines | 29 |
significant increase | 29 |
abdominal surgery | 29 |
month mortality | 29 |
hfnc group | 29 |
stroke volume | 29 |
large number | 29 |
even though | 29 |
muscle mass | 28 |
study aimed | 28 |
confidence intervals | 28 |
acute care | 28 |
body temperature | 28 |
prospectively collected | 28 |
coronary angiography | 28 |
scoring system | 28 |
care services | 28 |
may reduce | 28 |
severe pneumonia | 28 |
icu survivors | 28 |
requiring icu | 28 |
mortality risk | 28 |
infectious disease | 28 |
prospective randomized | 28 |
pulmonary artery | 28 |
study showed | 28 |
lactate dehydrogenase | 28 |
cause mortality | 28 |
aerosol therapy | 28 |
family members | 28 |
gene transfer | 28 |
patients presenting | 28 |
severe community | 28 |
improved survival | 28 |
mild disease | 28 |
ex vivo | 28 |
many patients | 28 |
viral rna | 27 |
acute hypoxemic | 27 |
sofa scores | 27 |
diabetes mellitus | 27 |
acute phase | 27 |
poor outcomes | 27 |
observational cohort | 27 |
chest wall | 27 |
may result | 27 |
supplementary information | 27 |
heart disease | 27 |
review board | 27 |
older patients | 27 |
continuous renal | 27 |
stage aki | 27 |
side effects | 27 |
endotracheal intubation | 27 |
corticosteroid therapy | 27 |
group compared | 27 |
medical icu | 27 |
innate immunity | 27 |
respiratory viruses | 27 |
important role | 27 |
year mortality | 27 |
clinical outcome | 27 |
respiratory disease | 27 |
correlation coefficient | 27 |
study protocol | 27 |
positive airway | 27 |
oxygen desaturation | 27 |
clinically relevant | 27 |
previously described | 26 |
type ii | 26 |
enteral nutrition | 26 |
recent study | 26 |
independent predictor | 26 |
united kingdom | 26 |
therapeutic anticoagulation | 26 |
acinetobacter baumannii | 26 |
gene therapy | 26 |
hospital survival | 26 |
final version | 26 |
upper respiratory | 26 |
written informed | 26 |
exhaled air | 26 |
independent predictors | 26 |
study reported | 26 |
compartment syndrome | 26 |
brainstem dysfunction | 26 |
aki stage | 26 |
ammatory response | 26 |
rank test | 26 |
coronavirus pneumonia | 26 |
three groups | 26 |
tie system | 26 |
ct scan | 26 |
hospital los | 26 |
artery bypass | 26 |
aerosol delivery | 26 |
randomised controlled | 26 |
blood oxygen | 26 |
symptom onset | 26 |
thrombin generation | 26 |
protective ventilation | 26 |
pneumonia patients | 26 |
host defense | 25 |
th cells | 25 |
venous catheter | 25 |
general icu | 25 |
bone marrow | 25 |
hoc analysis | 25 |
final approval | 25 |
icu care | 25 |
abdominal compartment | 25 |
cantly higher | 25 |
days vs | 25 |
every hours | 25 |
mitochondrial dna | 25 |
tract infection | 25 |
university hospitals | 25 |
ill covid | 25 |
real time | 25 |
early detection | 25 |
prolonged mechanical | 25 |
compared using | 25 |
fi brinogen | 25 |
cardiac index | 25 |
nosocomial pneumonia | 25 |
subgroup analysis | 25 |
spontaneous circulation | 25 |
induced pneumonia | 25 |
multivariate logistic | 25 |
systematic reviews | 25 |
enteral feeding | 25 |
oxidative stress | 25 |
common cause | 25 |
emergency room | 25 |
per day | 25 |
flow oxygen | 25 |
mean difference | 25 |
severe hypoxemia | 25 |
airway epithelial | 24 |
cardiovascular disease | 24 |
viral infections | 24 |
extracorporeal life | 24 |
low risk | 24 |
disseminated intravascular | 24 |
confi rmed | 24 |
fluid responsiveness | 24 |
survival rates | 24 |
pct levels | 24 |
information accompanies | 24 |
escherichia coli | 24 |
brain death | 24 |
intravascular coagulation | 24 |
success rate | 24 |
treated mice | 24 |
suspected infection | 24 |
maltophilia pneumonia | 24 |
randomly assigned | 24 |
white blood | 24 |
confirmed covid | 24 |
eff ectiveness | 24 |
see table | 24 |
ace expression | 24 |
small sample | 24 |
blood cultures | 24 |
directed therapy | 24 |
american thoracic | 24 |
monoclonal antibody | 24 |
cytokine levels | 24 |
immunocompromised patients | 24 |
statistical analyses | 24 |
study clinical | 24 |
severity scores | 24 |
single center | 24 |
general hospital | 24 |
wide range | 24 |
patient characteristics | 24 |
patients required | 24 |
low levels | 24 |
negative bacteria | 24 |
severe illness | 24 |
working group | 24 |
electronic medical | 24 |
gas exchange | 24 |
reference introduction | 24 |
ii scores | 23 |
regression analyses | 23 |
coronavirus infection | 23 |
mcg kg | 23 |
saudi arabia | 23 |
vascular endothelial | 23 |
diseases society | 23 |
intubation rate | 23 |
two different | 23 |
rsv lrtd | 23 |
glasgow coma | 23 |
patients underwent | 23 |
care workers | 23 |
data collected | 23 |
positive patients | 23 |
related organ | 23 |
among critically | 23 |
plasma concentrations | 23 |
host immune | 23 |
new zealand | 23 |
lung infl | 23 |
vital signs | 23 |
polymicrobial sepsis | 23 |
kidney disease | 23 |
syndromic rm | 23 |
cap patients | 23 |
hfot niv | 23 |
inflammatory responses | 23 |
myocardial injury | 23 |
gut microbiome | 23 |
clinical decision | 23 |
descriptive study | 23 |
normal range | 23 |
cystic fibrosis | 23 |
influenza patients | 23 |
patient outcome | 23 |
infl uence | 23 |
systemic corticosteroids | 23 |
empirical antimicrobial | 23 |
early diagnosis | 23 |
coma scale | 23 |
widely used | 23 |
positive pressure | 23 |
cohort studies | 23 |
rbc transfusion | 23 |
average age | 23 |
case reports | 23 |
first day | 23 |
lung parenchyma | 23 |
lactate levels | 23 |
quality improvement | 23 |
may explain | 23 |
significant reduction | 23 |
severity score | 23 |
analysed using | 22 |
iah acs | 22 |
patient populations | 22 |
hemodynamic instability | 22 |
interstitial pneumonia | 22 |
high levels | 22 |
inhalation injury | 22 |
head injury | 22 |
binding protein | 22 |
abdominal hypertension | 22 |
clinical research | 22 |
teaching hospital | 22 |
pleural effusion | 22 |
early identification | 22 |
pressure ventilation | 22 |
shock reversal | 22 |
bacterial infections | 22 |
severe traumatic | 22 |
network meta | 22 |
acute illness | 22 |
another study | 22 |
postoperative period | 22 |
disease non | 22 |
higher rate | 22 |
negative predictive | 22 |
patient groups | 22 |
may increase | 22 |
assessment method | 22 |
nutritional support | 22 |
controlled study | 22 |
respiratory mechanics | 22 |
air dispersion | 22 |
adverse outcomes | 22 |
time point | 22 |
flow rate | 22 |
blood culture | 22 |
supplementary material | 22 |
excluded patients | 22 |
clinical signs | 22 |
antibiotic resistance | 22 |
comorbidity index | 22 |
intubated patients | 22 |
venous blood | 22 |
hemodynamic parameters | 22 |
seven patients | 22 |
cell count | 22 |
longer duration | 22 |
peripheral blood | 21 |
study conducted | 21 |
pulmonary complications | 21 |
post hoc | 21 |
pulmonary hypertension | 21 |
cancer patients | 21 |
cognitive impairment | 21 |
regression models | 21 |
individual patient | 21 |
patient data | 21 |
remains unclear | 21 |
cox proportional | 21 |
secondary endpoints | 21 |
scoring systems | 21 |
neuromuscular blocking | 21 |
th day | 21 |
international guidelines | 21 |
tract infections | 21 |
space fraction | 21 |
included trials | 21 |
study population | 21 |
lymphocyte count | 21 |
tertiary hospital | 21 |
also found | 21 |
neuromuscular blockers | 21 |
cytokine production | 21 |
pulmonary vascular | 21 |
immune cells | 21 |
disease icu | 21 |
fatal cases | 21 |
worse outcomes | 21 |
electronic health | 21 |
see additional | 21 |
blunt chest | 21 |
hazard ratio | 21 |
novel influenza | 21 |
may provide | 21 |
hand hygiene | 21 |
gold standard | 21 |
icu treatment | 21 |
skeletal muscle | 21 |
organ function | 21 |
cisatracurium infusion | 21 |
strongly associated | 21 |
diffi cult | 21 |
care physicians | 21 |
blood gases | 21 |
pupillary light | 21 |
table shows | 21 |
processed eeg | 21 |
expiratory lung | 21 |
pulmonary infection | 21 |
results suggest | 21 |
higher incidence | 21 |
nosocomial infection | 21 |
european society | 21 |
mouse model | 21 |
vascular permeability | 20 |
beneficial effect | 20 |
author details | 20 |
group i | 20 |
arterial oxygen | 20 |
positive fluid | 20 |
chest pain | 20 |
aci group | 20 |
functional status | 20 |
liver failure | 20 |
nine patients | 20 |
icu setting | 20 |
plateau pressure | 20 |
alveolar epithelial | 20 |
klebsiella pneumoniae | 20 |
muscle weakness | 20 |
immune status | 20 |
surfactant protein | 20 |
study aims | 20 |
inflammatory cytokine | 20 |
cfu ml | 20 |
prognostic factors | 20 |
without ards | 20 |
hypercapnic respiratory | 20 |
supportive care | 20 |
hemorrhagic shock | 20 |
kg hour | 20 |
placebo group | 20 |
plasminogen activator | 20 |
lower mortality | 20 |
co removal | 20 |
illness severity | 20 |
worse outcome | 20 |
microbial metabolites | 20 |
neurologic outcome | 20 |
results indicate | 20 |
continuous infusion | 20 |
activated protein | 20 |
clinical presentation | 20 |
multivariable logistic | 20 |
chronic respiratory | 20 |
negative correlation | 20 |
injury severity | 20 |
icu delirium | 20 |
initial fluid | 20 |
lymphocyte ratio | 20 |
study shows | 20 |
fi brosis | 20 |
onset atrial | 20 |
literature search | 20 |
patients compared | 20 |
significant improvement | 20 |
also observed | 20 |
cumulative fluid | 19 |
healthcare providers | 19 |
inflammatory markers | 19 |
laryngeal edema | 19 |
life care | 19 |
care setting | 19 |
severe tbi | 19 |
conventional oxygen | 19 |
median duration | 19 |
tissue perfusion | 19 |
aged years | 19 |
longer icu | 19 |
first time | 19 |
deep sedation | 19 |
significantly decreased | 19 |
generalized linear | 19 |
mobility group | 19 |
ill children | 19 |
protective equipment | 19 |
prothrombin time | 19 |
respiratory symptoms | 19 |
five patients | 19 |
patients suffering | 19 |
regional strain | 19 |
abdominal wall | 19 |
infl uenza | 19 |
group versus | 19 |
acute coronary | 19 |
medical care | 19 |
spontaneously breathing | 19 |
demographic characteristics | 19 |
infected pneumonia | 19 |
brain tissue | 19 |
polymicrobial etiology | 19 |
ecmo initiation | 19 |
died within | 19 |
epithelial cell | 19 |
recent years | 19 |
tissue oxygenation | 19 |
ug ml | 19 |
patients years | 19 |
medical university | 19 |
significant correlation | 19 |
higher doses | 19 |
patients whose | 19 |
medical history | 19 |
time course | 19 |
rectus femoris | 19 |
antiviral therapy | 19 |
bacterial sepsis | 19 |
breathing trial | 19 |
successful extubation | 19 |
external validation | 19 |
positive association | 19 |
respiratory infection | 19 |
combination therapy | 19 |
organ transplant | 19 |
care resources | 19 |
kcal day | 19 |
emergency physicians | 19 |
mortality compared | 19 |
investigate whether | 19 |
hiv infection | 19 |
median icu | 19 |
hemodynamic monitoring | 19 |
renal disease | 19 |
defined according | 18 |
blocking agents | 18 |
group showed | 18 |
determined using | 18 |
future studies | 18 |
liver disease | 18 |
shear wave | 18 |
emergency medical | 18 |
study demonstrated | 18 |
survival benefit | 18 |
outcome data | 18 |
term outcomes | 18 |
single ventilator | 18 |
selection bias | 18 |
resistant pathogens | 18 |
influenza vaccination | 18 |
clinical aspects | 18 |
several limitations | 18 |
fluid management | 18 |
every patient | 18 |
relative risk | 18 |
lung recruitment | 18 |
chest compressions | 18 |
predict mortality | 18 |
arrest patients | 18 |
specifi city | 18 |
common risk | 18 |
clinical information | 18 |
music therapy | 18 |
least hours | 18 |
two studies | 18 |
ill medical | 18 |
medical staff | 18 |
functional outcome | 18 |
received ecmo | 18 |
cardiac function | 18 |
selected patients | 18 |
adult critically | 18 |
reperfusion injury | 18 |
pneumonia caused | 18 |
influenza season | 18 |
serum samples | 18 |
per year | 18 |
square test | 18 |
primary outcomes | 18 |
evaluation ii | 18 |
group box | 18 |
metabolic acidosis | 18 |
admission diagnosis | 18 |
ca patients | 18 |
patients date | 18 |
endothelial growth | 18 |
nitrogen balance | 18 |
ejection fraction | 18 |
ideal body | 18 |
serious adverse | 18 |
cannula oxygen | 18 |
early goal | 18 |
effi cacy | 18 |
whitney test | 18 |
days later | 18 |
organ donation | 18 |
light reflex | 18 |
severe forms | 18 |
datasets used | 18 |
multicenter randomized | 17 |
subarachnoid hemorrhage | 17 |
primary cause | 17 |
prolonged icu | 17 |
high incidence | 17 |
induced acute | 17 |
resource allocation | 17 |
venous thromboembolism | 17 |
clinical management | 17 |
chest trauma | 17 |
also associated | 17 |
better outcome | 17 |
control mice | 17 |
palliative care | 17 |
care providers | 17 |
th ese | 17 |
evaluated using | 17 |
mean duration | 17 |
term outcome | 17 |
multivariable analysis | 17 |
nuclear factor | 17 |
multiorgan failure | 17 |
showed significant | 17 |
lavage fluid | 17 |
clinical setting | 17 |
positive predictive | 17 |
arterial partial | 17 |
adjunctive therapy | 17 |
study including | 17 |
bacterial pneumonia | 17 |
american college | 17 |
small number | 17 |
lower levels | 17 |
sars patients | 17 |
creatinine clearance | 17 |
aerosolized drug | 17 |
icu physicians | 17 |
control measures | 17 |
tracheal intubation | 17 |
crp levels | 17 |
thromboembolic events | 17 |
undergoing cardiac | 17 |
shockable rhythm | 17 |
primary influenza | 17 |
three times | 17 |
main cause | 17 |
vasopressor therapy | 17 |
pathological findings | 17 |
tissue factor | 17 |
resistant bacteria | 17 |
confusion assessment | 17 |
study found | 17 |
circulating igm | 17 |
receiving mechanical | 17 |
outcomes among | 17 |
lactic acid | 17 |
one year | 17 |
preliminary results | 17 |
blood transfusions | 17 |
group ii | 17 |
death among | 17 |
tbi patients | 17 |
interstitial lung | 17 |
systolic blood | 17 |
internal medicine | 17 |
adult respiratory | 17 |
respiratory virus | 17 |
leading cause | 17 |
clinical benefit | 17 |
airway pressures | 17 |
high doses | 17 |
outcomes included | 17 |
may play | 17 |
diagnostic criteria | 17 |
chronic renal | 17 |
dysfunction syndrome | 17 |
using spss | 17 |
organ failures | 17 |
resuscitation rate | 17 |
adult icu | 17 |
sensitivity analyses | 17 |
charlson comorbidity | 17 |
bacterial ards | 16 |
antimicrobial stewardship | 16 |
macrophage activation | 16 |
cantly lower | 16 |
assess whether | 16 |
increasingly used | 16 |
cerebral ischemia | 16 |
deep vein | 16 |
center study | 16 |
cortisol levels | 16 |
serum lactate | 16 |
meier survival | 16 |
protective effect | 16 |
emergency departments | 16 |
organ support | 16 |
rater reliability | 16 |
right lung | 16 |
effi ciency | 16 |
human influenza | 16 |
south korea | 16 |
cci group | 16 |
neuraminidase inhibitors | 16 |
sepsis septic | 16 |
total number | 16 |
time interval | 16 |
hemodynamic stability | 16 |
multidisciplinary team | 16 |
cerebral perfusion | 16 |
mechanical power | 16 |
control patients | 16 |
new york | 16 |
parenteral nutrition | 16 |
details key | 16 |
positive correlation | 16 |
validation cohort | 16 |
disaster management | 16 |
vasopressor support | 16 |
experimental study | 16 |
tube placement | 16 |
icu population | 16 |
study groups | 16 |
clinical manifestations | 16 |
potential role | 16 |
potential therapeutic | 16 |
healthcare professionals | 16 |
improve survival | 16 |
fluid bolus | 16 |
renal dysfunction | 16 |
well tolerated | 16 |
increased morbidity | 16 |
beneficial effects | 16 |
local ethics | 16 |
identifi cation | 16 |
secondary infections | 16 |
quality control | 16 |
major surgery | 16 |
therapeutic interventions | 16 |
rheumatoid arthritis | 16 |
ecmo programs | 16 |
respiratory acidosis | 16 |
requiring intensive | 16 |
venous pressure | 16 |
time period | 16 |
nosocomial transmission | 16 |
patients enrolled | 16 |
including patients | 16 |
continuous data | 16 |
clinical diagnosis | 16 |
union hospital | 16 |
secondary analysis | 16 |
modifi ed | 16 |
respiratory insufficiency | 16 |
sars outbreak | 16 |
acute brain | 16 |
therapeutic targets | 16 |
sublingual microcirculation | 16 |
ml cmh | 16 |
poor neurological | 16 |
hours post | 16 |
respiratory samples | 16 |
control study | 16 |
gas flow | 16 |
rst hours | 16 |
early pn | 16 |
studies using | 16 |
low tidal | 16 |
outcome measures | 16 |
organ damage | 16 |
temperature management | 16 |
lung damage | 16 |
acute pancreatitis | 16 |
also significantly | 16 |
solid organ | 16 |
ace angiotensin | 16 |
study performed | 16 |
pneumocystis carinii | 16 |
vena cava | 16 |
acute ischemic | 16 |
health record | 16 |
related complications | 16 |
mortality associated | 16 |
trend toward | 16 |
secondary infection | 16 |
based therapies | 16 |
community acquired | 16 |
icu staff | 16 |
group received | 16 |
resource utilization | 15 |
gas analysis | 15 |
citrate anticoagulation | 15 |
score matching | 15 |
least two | 15 |
primary care | 15 |
mental health | 15 |
oxygen consumption | 15 |
refractory hypoxemia | 15 |
treated patients | 15 |
control groups | 15 |
patients developed | 15 |
reverse transcriptase | 15 |
pulmonary infiltrates | 15 |
care management | 15 |
without dad | 15 |
laboratory data | 15 |
ten patients | 15 |
authors contributed | 15 |
high rate | 15 |
vv ecmo | 15 |
wilcoxon rank | 15 |
decompressive laparotomy | 15 |
patients presented | 15 |
large cohort | 15 |
thrombotic complications | 15 |
screening registry | 15 |
blood products | 15 |
gastrointestinal tract | 15 |
cardiac dysfunction | 15 |
evidence suggests | 15 |
randomized study | 15 |
artery disease | 15 |
baseline levels | 15 |
cytokine release | 15 |
relatively low | 15 |
iav infection | 15 |
unit admission | 15 |
brainstem reflexes | 15 |
survival analysis | 15 |
first study | 15 |
significantly improved | 15 |
tyrosine kinase | 15 |
liver transplantation | 15 |
without sepsis | 15 |
respiratory secretions | 15 |
lung pathology | 15 |
observation period | 15 |
venous return | 15 |
hypoxemic patients | 15 |
weaning failure | 15 |
ldh levels | 15 |
empirical therapy | 15 |
altman analysis | 15 |
bloodstream infection | 15 |
lung diseases | 15 |
elevated tni | 15 |
within months | 15 |
pediatric patients | 15 |
therapeutic intervention | 15 |
pulmonary function | 15 |
uid balance | 15 |
nafamostat mesylate | 15 |
organ dysfunctions | 15 |
intellectual content | 15 |
medical resources | 15 |
associated coagulopathy | 15 |
experimental sepsis | 15 |
term survival | 15 |
eight patients | 15 |
positive results | 15 |
normally distributed | 15 |
diaphragm thickness | 15 |
older age | 15 |
breathing trials | 15 |
icu readmission | 15 |
inflammatory biomarkers | 15 |
cystic fi | 15 |
neuromuscular blockade | 15 |
quality assessment | 15 |
may require | 15 |
medical record | 15 |
antibiotic use | 15 |
adult intensive | 15 |
lung aeration | 15 |
natriuretic peptide | 15 |
pulmonary congestion | 15 |
face mask | 15 |
early stage | 15 |
general anesthesia | 15 |
occupancy rate | 15 |
cerebrospinal fluid | 15 |
medical staffs | 15 |
inflammatory diseases | 15 |
patients discharged | 15 |
diagnostic tests | 15 |
long term | 15 |
significant risk | 15 |
chest radiograph | 15 |
map mmhg | 15 |
full text | 15 |
antimicrobial resistance | 15 |
sensitivity analysis | 15 |
mean length | 15 |
rbc transfusions | 15 |
survival probability | 15 |
viral clearance | 15 |
data regarding | 15 |
high level | 15 |
bacterial clearance | 15 |
study suggests | 15 |
vein thrombosis | 15 |
patient selection | 14 |
microbiological diagnosis | 14 |
empirical antibiotic | 14 |
respiratory drive | 14 |
multicenter prospective | 14 |
rescue therapy | 14 |
rhesus macaques | 14 |
studies reported | 14 |
analysis using | 14 |
days post | 14 |
currently available | 14 |
four groups | 14 |
elevated renin | 14 |
communityacquired pneumonia | 14 |
major trauma | 14 |
severe lung | 14 |
characteristic curve | 14 |
picu stay | 14 |
system dysfunction | 14 |
retrospective studies | 14 |
pulmonary oedema | 14 |
differ significantly | 14 |
healthy adults | 14 |
postoperative delirium | 14 |
base excess | 14 |
hospital icu | 14 |
renal impairment | 14 |
prospective studies | 14 |
regional lung | 14 |
better outcomes | 14 |
transfusion strategy | 14 |
north america | 14 |
venous oxygen | 14 |
standard therapy | 14 |
reduced mortality | 14 |
extubation respiratory | 14 |
burn patients | 14 |
considered significant | 14 |
right ventricular | 14 |
peep increase | 14 |
term cognitive | 14 |
common complication | 14 |
ventilated infants | 14 |
amino acids | 14 |
study using | 14 |
clostridium difficile | 14 |
international consensus | 14 |
published data | 14 |
time spent | 14 |
care system | 14 |
diagnostic performance | 14 |
randomized trials | 14 |
transcranial doppler | 14 |
previous reports | 14 |
personal protective | 14 |
fibrinogen concentrate | 14 |
committee approval | 14 |
support methods | 14 |
surgical procedure | 14 |
decision support | 14 |
missing data | 14 |
secondary outcome | 14 |
recently published | 14 |
linear mixed | 14 |
postextubation stridor | 14 |
fl uids | 14 |
chart review | 14 |
mm hg | 14 |
improve clinical | 14 |
deeply sedated | 14 |
bacterial coinfection | 14 |
clinical significance | 14 |
pregnant women | 14 |
linear model | 14 |
empiric antibiotic | 14 |
partial thromboplastin | 14 |
transfusion requirements | 14 |
cardiac surgical | 14 |
published studies | 14 |
patients according | 14 |
multiple trauma | 14 |
significantly elevated | 14 |
adhesion molecule | 14 |
cecal ligation | 14 |
interim guidance | 14 |
variables associated | 14 |
high mobility | 14 |
therapeutic target | 14 |
left ventricle | 14 |
less frequently | 14 |
lung inflammation | 14 |
procedural sedation | 14 |
lower risk | 14 |
research ethics | 14 |
prediction model | 14 |
nucleic acid | 14 |
ventilator circuit | 14 |
lactate level | 14 |
prophylactic anticoagulation | 14 |
severe infection | 14 |
disease patients | 14 |
odds ratios | 14 |
bed occupancy | 14 |
cell types | 14 |
patient management | 14 |
kdigo criteria | 14 |
initial rhythm | 14 |
pulmonary blood | 14 |
carinii pneumonia | 14 |
one case | 14 |
affiliations none | 14 |
cardiac troponin | 14 |
time pcr | 14 |
spectrum antibiotics | 14 |
upper airway | 14 |
personal fees | 14 |
also showed | 14 |
resource use | 14 |
increased levels | 14 |
invasive candidiasis | 14 |
acute pulmonary | 14 |
mechanical ventilator | 14 |
chronic heart | 14 |
immunosorbent assay | 14 |
human lung | 14 |
patients will | 14 |
rapid response | 14 |
making process | 14 |
drug resistance | 14 |
icu resources | 14 |
phase ii | 14 |
highly pathogenic | 14 |
cerebral blood | 14 |
severe iav | 14 |
first week | 14 |
icu due | 14 |
task force | 14 |
failure requiring | 14 |
cerebral oxygenation | 14 |
consensus guidelines | 14 |
findings suggest | 14 |
sars coronavirus | 14 |
thromboplastin time | 14 |
care hospital | 14 |
ill adult | 13 |
drug resistant | 13 |
predicted body | 13 |
cap caused | 13 |
right heart | 13 |
bacterial pathogens | 13 |
improves survival | 13 |
therapy group | 13 |
lung protective | 13 |
endotracheal suctioning | 13 |
glucose levels | 13 |
one hour | 13 |
chronic kidney | 13 |
years ago | 13 |
planned extubation | 13 |
suspected influenza | 13 |
high morbidity | 13 |
less likely | 13 |
peep levels | 13 |
mixed model | 13 |
significantly correlated | 13 |
alveolar dead | 13 |
second group | 13 |
protocol group | 13 |
requiring renal | 13 |
targeted temperature | 13 |
resistant staphylococcus | 13 |
curve analysis | 13 |
endothelial dysfunction | 13 |
acute exacerbation | 13 |
aerosol deposition | 13 |
individual patients | 13 |
genetic association | 13 |
mechanical ventilators | 13 |
past years | 13 |
vap patients | 13 |
may represent | 13 |
investigated whether | 13 |
sum test | 13 |
liver injury | 13 |
sepsis cohort | 13 |
drug therapy | 13 |
pneumonia severity | 13 |
organ systems | 13 |
elective surgery | 13 |
may influence | 13 |
ards criteria | 13 |
recruited pixels | 13 |
ventilator support | 13 |
admitted patients | 13 |
increased hospital | 13 |
lower tidal | 13 |
descriptive statistics | 13 |
staffi ng | 13 |
major abdominal | 13 |
survival curves | 13 |
ventilation time | 13 |
vessel density | 13 |
lung regions | 13 |
molecular weight | 13 |
squared test | 13 |
cutoff value | 13 |
animal model | 13 |
icu nurses | 13 |
attending physician | 13 |
blood fl | 13 |
available data | 13 |
cell counts | 13 |
stage renal | 13 |
early mobilization | 13 |
origin influenza | 13 |
elevated levels | 13 |
relatively small | 13 |
prowess trial | 13 |
successful weaning | 13 |
cytokine response | 13 |
pc activity | 13 |
bal fluid | 13 |
pneumocystis pneumonia | 13 |
influenza viral | 13 |
well known | 13 |
cognitive function | 13 |
last years | 13 |
previously published | 13 |
risk assessment | 13 |
vascular resistance | 13 |
lung deposition | 13 |
may reflect | 13 |
disease progression | 13 |
care society | 13 |
plasma exchange | 13 |
based approaches | 13 |
delirium screening | 13 |
current practice | 13 |
glasgow outcome | 13 |
sedated patients | 13 |
indirect calorimetry | 13 |
benefi cial | 13 |
abdominal pain | 13 |
activation syndrome | 13 |
literature review | 13 |
venous extracorporeal | 13 |
airway complications | 13 |
congestive heart | 13 |
kg day | 13 |
authors thank | 13 |
may occur | 13 |
benefi ts | 13 |
mean value | 13 |
clinical use | 13 |
sepsis diagnosis | 13 |
flow velocity | 13 |
renal scintigraphy | 13 |
laboratory findings | 13 |
cell death | 13 |
phase iii | 13 |
methanol poisoning | 13 |
two independent | 13 |
gut microbial | 13 |
active bleeding | 13 |
undergoing elective | 13 |
spike protein | 13 |
operator reliability | 13 |
underlying disease | 13 |
patient group | 13 |
mask ventilation | 13 |
systemic infl | 13 |
respiratory viral | 13 |
traumatic stress | 13 |
epidemiology studies | 13 |
developing severe | 13 |
response rate | 13 |
ecmo duration | 13 |
linked immunosorbent | 13 |
dendritic cells | 13 |
respiratory illness | 13 |
murine model | 13 |
protein levels | 13 |
identified patients | 13 |
may decrease | 13 |
study date | 13 |
adjunctive treatment | 13 |
increased significantly | 13 |
patients develop | 13 |
discharged alive | 13 |
glucose control | 13 |
stimulating factor | 13 |
confirmed cases | 13 |
care settings | 12 |
pneumonia due | 12 |
saline bolus | 12 |
care admission | 12 |
extubated patients | 12 |
rib fractures | 12 |
cicu admission | 12 |
among icu | 12 |
chest physiotherapy | 12 |
nutrition support | 12 |
mean time | 12 |
america american | 12 |
severe blunt | 12 |
viral vectors | 12 |
several days | 12 |
two hospitals | 12 |
gram negative | 12 |
vascular leakage | 12 |
patients due | 12 |
expiratory flow | 12 |
apache iv | 12 |
difficile infection | 12 |
dysfunction failure | 12 |
daily nursing | 12 |
elevated ck | 12 |
inferior vena | 12 |
steady state | 12 |
mean apache | 12 |
retrospective chart | 12 |
serum concentrations | 12 |
score ii | 12 |
fi eld | 12 |
tissue damage | 12 |
standard deviations | 12 |
virus infections | 12 |
risk ratio | 12 |
ards may | 12 |
median length | 12 |
cell function | 12 |
non critical | 12 |
administering dexmedetomidine | 12 |
index hospitalization | 12 |
healthy people | 12 |
particle flow | 12 |
reverse transcription | 12 |
richmond agitation | 12 |
healthcare costs | 12 |
major societal | 12 |
aki patients | 12 |
hyaline membrane | 12 |
patients reported | 12 |
ventilation strategy | 12 |
hypersecretive patients | 12 |
ventilator dependence | 12 |
ventilatorassociated pneumonia | 12 |
qsofa score | 12 |
patients met | 12 |
treating patients | 12 |
mean values | 12 |
severity index | 12 |
coeffi cient | 12 |
early pp | 12 |
antibiotic stewardship | 12 |
hospital stays | 12 |
retrospective design | 12 |
sepsis management | 12 |
iu ml | 12 |
controlled ventilation | 12 |
three days | 12 |
cci patients | 12 |
type mice | 12 |
study cohort | 12 |
two reviewers | 12 |
tract disease | 12 |
patients within | 12 |
glomerular filtration | 12 |
steroid therapy | 12 |
antimicrobial agents | 12 |
wall compliance | 12 |
human covid | 12 |
inspiratory pressure | 12 |
high sensitivity | 12 |
rv lv | 12 |
cell survival | 12 |
crypt cells | 12 |
studied patients | 12 |
ecmo weaning | 12 |
general population | 12 |
creatine kinase | 12 |
early initiation | 12 |
clot microstructure | 12 |
among hospitalized | 12 |
eligible patients | 12 |
controlled clinical | 12 |
perfusion pressure | 12 |
proportional hazards | 12 |
cardiac intensive | 12 |
training cohort | 12 |
recent meta | 12 |
ace receptor | 12 |
several factors | 12 |
chronic lung | 12 |
driving pressures | 12 |
clinical impact | 12 |
mnutric score | 12 |
fluid challenge | 12 |
kidney function | 12 |
medical treatment | 12 |
single dose | 12 |
tie signalling | 12 |
sustaining treatment | 12 |
laboratory tests | 12 |
bypass grafting | 12 |
requiring hospitalization | 12 |
effects model | 12 |
optimal cutoff | 12 |
comorbid conditions | 12 |
also compared | 12 |
adult critical | 12 |
different types | 12 |
decreased significantly | 12 |
transcription factor | 12 |
family satisfaction | 12 |
acute disease | 12 |
improve outcomes | 12 |
failure due | 12 |
deceased patients | 12 |
less frequent | 12 |
pain management | 12 |
troponin i | 12 |
much higher | 12 |
lung epithelial | 12 |
fecal samples | 12 |
positive blood | 12 |
serum na | 12 |
mental status | 12 |
adaptive immune | 12 |
anticholinergic activity | 12 |
patients survived | 12 |
status epilepticus | 12 |
using standard | 12 |
frequently used | 12 |
median sofa | 12 |
prospective multicenter | 12 |
pearson correlation | 12 |
mayo clinic | 12 |
multiple testing | 12 |
year study | 12 |
organ perfusion | 12 |
unsuspected influenza | 12 |
took place | 12 |
improve patient | 12 |
patients require | 12 |
current evidence | 12 |
systolic function | 12 |
expression levels | 12 |
data generated | 12 |
two cases | 12 |
neurological manifestations | 12 |
clinical parameters | 12 |
twice daily | 12 |
mortality prediction | 12 |
major cause | 12 |
per cent | 12 |
median apache | 12 |
sectional study | 12 |
physical function | 12 |
outcome scale | 12 |
oxygen fraction | 12 |
jugular vein | 12 |
ecmo flow | 12 |
results showed | 12 |
membrane lung | 12 |
retrospectively analyzed | 12 |
outcome measure | 12 |
ventilator asynchrony | 12 |
kingdom critical | 12 |
kcal kg | 12 |
repeated measures | 12 |
inflammatory effects | 12 |
surgical intensive | 12 |
treatment options | 12 |
plateau pressures | 12 |
associated acute | 12 |
low sensitivity | 12 |
respiratory pathogens | 11 |
surface area | 11 |
immunodeficiency virus | 11 |
six months | 11 |
severe pandemic | 11 |
limited evidence | 11 |
effi cient | 11 |
levels may | 11 |
intracranial hypertension | 11 |
trial registration | 11 |
brainstem lesions | 11 |
increased survival | 11 |
days mortality | 11 |
complications related | 11 |
negative bacilli | 11 |
operating characteristics | 11 |
ventilation mode | 11 |
gastric emptying | 11 |
rat model | 11 |
human coronavirus | 11 |
severe aki | 11 |
renal transplant | 11 |
data using | 11 |
ventilation distribution | 11 |
pulse contour | 11 |
patient records | 11 |
specific enolase | 11 |
associated complications | 11 |
ultrasound guidance | 11 |
viral loads | 11 |
immune suppression | 11 |
independent association | 11 |
chronic dysglycemia | 11 |
overall survival | 11 |
lactam antibiotics | 11 |
early albumin | 11 |
care admissions | 11 |
host cells | 11 |
lung mechanics | 11 |
abdominal pressure | 11 |
renal clearance | 11 |
oxygenation index | 11 |
apache score | 11 |
venoarterial extracorporeal | 11 |
video laryngoscope | 11 |
ivc diameter | 11 |
van der | 11 |
human immunodeficiency | 11 |
data management | 11 |
endothelial permeability | 11 |
fluid infusion | 11 |
epithelial lining | 11 |
study comparing | 11 |
one hundred | 11 |
favorable neurologic | 11 |
tranexamic acid | 11 |
dp dtmax | 11 |
published article | 11 |
higher hospital | 11 |
estimate rated | 11 |
blood volume | 11 |
blood sugar | 11 |
clinical evidence | 11 |
pneumocystis jirovecii | 11 |
respiratory diseases | 11 |
diff er | 11 |
consensus definitions | 11 |
analysis revealed | 11 |
defi nitions | 11 |
clinical severity | 11 |
higher level | 11 |
natural killer | 11 |
less severe | 11 |
using data | 11 |
japan critical | 11 |
national health | 11 |
overall cohort | 11 |
multiorgan dysfunction | 11 |
healthy lungs | 11 |
acceptable range | 11 |
stress raisers | 11 |
adrenal insufficiency | 11 |
available online | 11 |
preliminary data | 11 |
mg day | 11 |
management strategies | 11 |
porcine model | 11 |
mas axis | 11 |
clinical suspicion | 11 |
total cost | 11 |
cell injury | 11 |
postoperative care | 11 |
may affect | 11 |
stem cells | 11 |
isofl urane | 11 |
day period | 11 |
ecmo circuit | 11 |
biomarker levels | 11 |
develop severe | 11 |
dic score | 11 |
primary objective | 11 |
similar results | 11 |
bolus injection | 11 |
lung perfusion | 11 |
data warehouse | 11 |
reduce mortality | 11 |
icu bed | 11 |
berlin criteria | 11 |
higher apache | 11 |
sedation scale | 11 |
particle size | 11 |
healthy individuals | 11 |
increasing number | 11 |
mixed icu | 11 |
fi brinolysis | 11 |
prolonged viral | 11 |
rv function | 11 |
extubation stridor | 11 |
system resistance | 11 |
significant morbidity | 11 |
system compliance | 11 |
versus non | 11 |
icu management | 11 |
haematological malignancy | 11 |
lv ratio | 11 |
will need | 11 |
spinal cord | 11 |
neurological outcomes | 11 |
physical restraint | 11 |
evoked potentials | 11 |
references introduction | 11 |
multiple comparisons | 11 |
younger patients | 11 |
filtration rate | 11 |
adults hospitalized | 11 |
central hospital | 11 |
pediatric intensive | 11 |
statistical heterogeneity | 11 |
nasal high | 11 |
coronavirus infections | 11 |
percutaneous coronary | 11 |
hospital costs | 11 |
search strategy | 11 |
ratio group | 11 |
ischemic injury | 11 |
older adults | 11 |
nasal oxygen | 11 |
consensus statement | 11 |
dvt prophylaxis | 11 |
standard treatment | 11 |
signifi cance | 11 |
likely due | 11 |
biceps brachii | 11 |
acc mentions | 11 |
trend towards | 11 |
signal transduction | 11 |
ng tube | 11 |
correlation coeffi | 11 |
bystander cpr | 11 |
clinically important | 11 |
overdistended pixels | 11 |
pleural fluid | 11 |
healthcare systems | 11 |
may need | 11 |
improved outcomes | 11 |
haemoglobin concentrations | 11 |
endothelial barrier | 11 |
consensus conference | 11 |
binding domain | 11 |
recombinant human | 11 |
induced pulmonary | 11 |
data available | 11 |
visitation restrictions | 11 |
adult icus | 11 |
activity assay | 11 |
significant association | 11 |
chronic liver | 11 |
better understanding | 11 |
retrospective data | 11 |
icu time | 11 |
ohca patients | 11 |
copies ml | 11 |
severe organ | 11 |
organ transplantation | 11 |
endotracheal tubes | 11 |
handheld devices | 11 |
mortality benefit | 11 |
negative pressure | 11 |
clinical condition | 11 |
va ecmo | 11 |
unfractionated heparin | 11 |
syndrome network | 11 |
care bundle | 11 |
clinical pulmonary | 11 |
ventilator days | 11 |
icu day | 11 |
handheld device | 11 |
immortal time | 11 |
derived hepcidin | 11 |
remaining patients | 11 |
clinical criteria | 11 |
therapy based | 11 |
neurological examination | 11 |
early stages | 11 |
male patients | 11 |
without significant | 11 |
classifi ed | 11 |
oxygen supply | 11 |
lung collapse | 11 |
major role | 11 |
liver function | 11 |
significant variation | 11 |
important factor | 11 |
national audit | 11 |
predictive power | 11 |
also reported | 11 |
previously healthy | 11 |
commercially available | 11 |
normal values | 11 |
human gut | 11 |
whole body | 11 |
received invasive | 11 |
inspiratory flow | 11 |
adverse event | 11 |
health system | 11 |
short term | 11 |
nasogastric tube | 11 |
immune cell | 10 |
massive transfusion | 10 |
routine use | 10 |
blood product | 10 |
septic episode | 10 |
pneumonia requiring | 10 |
inoculated mice | 10 |
small intestine | 10 |
vte prophylaxis | 10 |
relative change | 10 |
data protection | 10 |
stress levels | 10 |
early extubation | 10 |
lining fluid | 10 |
weight heparin | 10 |
congenital heart | 10 |
nutrition delivery | 10 |
irreversible dysfunction | 10 |
single centre | 10 |
frozen plasma | 10 |
prediction models | 10 |
readmission rates | 10 |
coronary intervention | 10 |
higher severity | 10 |
phase i | 10 |
participating centers | 10 |
refractory septic | 10 |
warning score | 10 |
tract samples | 10 |
lung elastance | 10 |
urinary antigen | 10 |
mucociliary clearance | 10 |
nonhuman primates | 10 |
mononuclear cells | 10 |
high positive | 10 |
multivariable analyses | 10 |
augmented renal | 10 |
normal saline | 10 |
random forest | 10 |
insulin resistance | 10 |
insuffi cient | 10 |
higher number | 10 |
host cell | 10 |
days prior | 10 |
increased rates | 10 |
intravascular volume | 10 |
study results | 10 |
patients diagnosed | 10 |
clinical cure | 10 |
sepsis onset | 10 |
plasma samples | 10 |
care team | 10 |
search terms | 10 |
flail chest | 10 |
factors may | 10 |
hospitalised patients | 10 |
clinical implications | 10 |
lung transplantation | 10 |
one third | 10 |
patients supported | 10 |
therapy versus | 10 |
information regarding | 10 |
differed significantly | 10 |
performance category | 10 |
will require | 10 |
general wards | 10 |
influenza testing | 10 |
survival group | 10 |
arterial lactate | 10 |
delivery via | 10 |
ethical committee | 10 |
aromatic microbial | 10 |
intravenous peramivir | 10 |
drug deposition | 10 |
peep cmh | 10 |
function testing | 10 |
questions related | 10 |
restrictive transfusion | 10 |
evaluate whether | 10 |
rst week | 10 |
circulatory support | 10 |
patients ventilated | 10 |
therapeutic range | 10 |
weighted mean | 10 |
hepcidin knockdown | 10 |
antibiotic administration | 10 |
arterial catheters | 10 |
china clinical | 10 |
guidelines recommend | 10 |
hours later | 10 |
preferred reporting | 10 |
multivariate cox | 10 |
gastric acid | 10 |
multicenter retrospective | 10 |
among others | 10 |
clinical review | 10 |
liberal strategy | 10 |
severe pain | 10 |
related quality | 10 |
beneficial role | 10 |
early intervention | 10 |
lung ischemia | 10 |
sleep deprivation | 10 |
internal jugular | 10 |
ct scans | 10 |
kg ideal | 10 |
treat patients | 10 |
first draft | 10 |
ethical approval | 10 |
inhospital mortality | 10 |
arterial carbon | 10 |
publication bias | 10 |
noninvasive mechanical | 10 |
head ct | 10 |
baseline severity | 10 |
ulcer prophylaxis | 10 |
high respiratory | 10 |
early warning | 10 |
associated virus | 10 |
antimicrobial susceptibility | 10 |
methods used | 10 |
severe sars | 10 |
positive endexpiratory | 10 |
wallis test | 10 |
based protocol | 10 |
experimental studies | 10 |
injured patients | 10 |
important intellectual | 10 |
muscle wasting | 10 |
induced coagulopathy | 10 |
stress disorder | 10 |
ventilation strategies | 10 |
supine position | 10 |
reporting items | 10 |
clinical stability | 10 |
treatment option | 10 |
longer length | 10 |
lv function | 10 |
molecular techniques | 10 |
also noted | 10 |
retrospectively reviewed | 10 |
standard care | 10 |
high dose | 10 |
limited resources | 10 |
bacterial co | 10 |
mild patients | 10 |
lithium chloride | 10 |
classification system | 10 |
autoimmune diseases | 10 |
medical reference | 10 |
cerebral performance | 10 |
tissue samples | 10 |
emergency care | 10 |
ventricular fibrillation | 10 |
amino acid | 10 |
anticoagulation regimens | 10 |
cell apoptosis | 10 |
respiratory variations | 10 |
cardiac failure | 10 |
data acquisition | 10 |
random effects | 10 |
substantial contributions | 10 |
complications associated | 10 |
lower incidence | 10 |
severe head | 10 |
roc analysis | 10 |
infl uenzae | 10 |
serum concentration | 10 |
case mix | 10 |
hazard ratios | 10 |
advanced age | 10 |
care syndrome | 10 |
novel method | 10 |
laboratory testing | 10 |
care interventions | 10 |
science foundation | 10 |
early phase | 10 |
immunosuppressed patients | 10 |
median number | 10 |
studies reporting | 10 |
mitochondrial dysfunction | 10 |
clinical phenotype | 10 |
magnetic resonance | 10 |
high prevalence | 10 |
complement activation | 10 |
groups according | 10 |
ammatory responses | 10 |
sepsis syndrome | 10 |
electrical activity | 10 |
mechanical thromboprophylaxis | 10 |
ml vs | 10 |
adverse outcome | 10 |
brain damage | 10 |
multiplex pcr | 10 |
preliminary study | 10 |
multicenter cohort | 10 |
per protocol | 10 |
white matter | 10 |
total hospital | 10 |
rank sum | 10 |
endotoxin activity | 10 |
well understood | 10 |
aki mortality | 10 |
cantly increased | 10 |
required mechanical | 10 |
artificial intelligence | 10 |
postoperative complications | 10 |
predicted mortality | 10 |
ventilator use | 10 |
potential benefits | 10 |
disease process | 10 |
restrictive group | 10 |
spo i | 10 |
insufficient data | 10 |
staff members | 10 |
final nebulisation | 10 |
pilot randomized | 10 |
improve oxygenation | 10 |
resistant organisms | 10 |
burn injury | 10 |
treatment group | 10 |
electronic supplementary | 10 |
ventilated icu | 10 |
frequency chest | 10 |
text view | 10 |
handheld computer | 10 |
aerosol drug | 10 |
acutely ill | 10 |
cardiothoracic surgery | 10 |
cardiac tamponade | 10 |
fluid removal | 10 |
diagnostic test | 10 |
proinflammatory cytokines | 10 |
diagnostic testing | 10 |
clinical relevance | 10 |
patient mortality | 10 |
confi rm | 10 |
cap admitted | 10 |
better survival | 10 |
myocardial ischemia | 10 |
sepsis severity | 10 |
oseltamivir treatment | 10 |
categorical data | 10 |
recent data | 10 |
mutant mice | 10 |
allowed us | 10 |
affiliations key | 10 |
identifying patients | 10 |
muscle quality | 10 |
intracerebral hemorrhage | 10 |
therapeutic strategy | 10 |
negative impact | 10 |
significant impact | 10 |
sepsis care | 10 |
underlying diseases | 10 |
infection may | 10 |
viral presence | 10 |
animal studies | 10 |
nursing procedures | 10 |
bed icu | 10 |
minute ventilation | 10 |
electronic patient | 10 |
ventilation modes | 10 |
severe pulmonary | 10 |
segment elevation | 10 |
increased odds | 10 |
online survey | 10 |
information system | 10 |
higher rates | 10 |
disaster medicine | 10 |
clotting time | 10 |
cd cd | 10 |
membrane formation | 10 |
confi rmation | 10 |
diuresis protocol | 10 |
risk score | 10 |
infections caused | 10 |
slightly higher | 10 |
dependent manner | 10 |
cancer surgery | 10 |
guided therapy | 10 |
pain score | 10 |
angiotensin system | 10 |
comatose patients | 10 |
diagnostic value | 9 |
sepsis protocol | 9 |
predictive ability | 9 |
resonance imaging | 9 |
mycobacterium tuberculosis | 9 |
knowledge regarding | 9 |
negative pathogens | 9 |
transit time | 9 |
transpulmonary pressure | 9 |
fatty acids | 9 |
using mixed | 9 |
secondary comparison | 9 |
mg iv | 9 |
systemic levels | 9 |
care bundles | 9 |
gas parameters | 9 |
study patients | 9 |
validation set | 9 |
also excluded | 9 |
showed good | 9 |
infusion rate | 9 |
vitro study | 9 |
methods patients | 9 |
hemoperfusion cartridge | 9 |
done using | 9 |
epithelial injury | 9 |
colleagues found | 9 |
therapeutic approaches | 9 |
negative results | 9 |
high viral | 9 |
annual update | 9 |
may allow | 9 |
various respiratory | 9 |
pcr assay | 9 |
barrier function | 9 |
multidisciplinary committee | 9 |
resistance patterns | 9 |
first dose | 9 |
continuous positive | 9 |
xa levels | 9 |
may predict | 9 |
patient demographics | 9 |
regional hospital | 9 |
glycocalyx shedding | 9 |
septic encephalopathy | 9 |
angiotensin converting | 9 |
refeeding syndrome | 9 |
altered immune | 9 |
log rank | 9 |
cov infections | 9 |
neuraminidase inhibitor | 9 |
nasopharyngeal swabs | 9 |
factor alpha | 9 |
hemophagocytic lymphohistiocytosis | 9 |
interquartile ranges | 9 |
using real | 9 |
care delivery | 9 |
shock due | 9 |
second day | 9 |
peep level | 9 |
severe burn | 9 |
rna clearance | 9 |
infection prevention | 9 |
tricc trial | 9 |
societal guidelines | 9 |
main risk | 9 |
indian subset | 9 |
roc curves | 9 |
liquid chromatography | 9 |
retrospective review | 9 |
retrospectively collected | 9 |
nutritional risk | 9 |
three icus | 9 |
life decisions | 9 |
elf concentrations | 9 |
corticosteroid use | 9 |
extracorporeal circulation | 9 |
resuscitation council | 9 |
respiratory muscle | 9 |
withdraw therapy | 9 |
cell membrane | 9 |
similar clinical | 9 |
cerebral artery | 9 |
severe trauma | 9 |
withdrawn due | 9 |
fractured ribs | 9 |
developed ards | 9 |
positive bacteria | 9 |
tissue plasminogen | 9 |
disease classification | 9 |
intracellular iron | 9 |
data interpretation | 9 |
surgical procedures | 9 |
oxygen species | 9 |
heart score | 9 |
subgroup analyses | 9 |
kg bw | 9 |
intercostal space | 9 |
many factors | 9 |
secondary endpoint | 9 |
high frequency | 9 |
sample collection | 9 |
third international | 9 |
healthcare staff | 9 |
food intake | 9 |
low vt | 9 |
higher serum | 9 |
groups based | 9 |
preventive use | 9 |
genetic variants | 9 |
neurological status | 9 |
quantifi ed | 9 |
triage tool | 9 |
late pn | 9 |
reactive oxygen | 9 |
cardiac arrests | 9 |
biomed central | 9 |
resting energy | 9 |
crucial role | 9 |
scarce resources | 9 |
muscle strength | 9 |
poorly understood | 9 |
susceptibility testing | 9 |
drug administration | 9 |
admission diagnoses | 9 |
feedback function | 9 |
independent variables | 9 |
increased icu | 9 |
ca cpr | 9 |
found online | 9 |